Abstract
SYNGAP1 haploinsufficiency results in a developmental and epileptic encephalopathy (DEE) causing generalized epilepsies accompanied by a spectrum of neurodevelopmental symptoms. Concerning interictal epileptiform discharges (IEDs) in electroencephalograms (EEG), potential biomarkers have been postulated, including changes in background activity, fixation-off sensitivity (FOS) or eye closure sensitivity (ECS). In this study we clinically evaluate a new cohort of 36 SYNGAP1-DEE individuals. Standardized questionnaires were employed to collect clinical, electroencephalographic and genetic data. We investigated electroencephalographic findings, focusing on the cortical distribution of interictal abnormalities and their changes with age. Among the 36 SYNGAP1-DEE cases 16 presented variants in the SYNGAP1 gene that had never been previously reported. The mean age of diagnosis was 8 years and 8 months, ranging from 2 to 17 years, with 55.9% being male. All subjects had global neurodevelopmental/language delay and behavioral abnormalities; 83.3% had moderate to profound intellectual disability (ID), 91.7% displayed autistic traits, 73% experienced sleep disorders and 86.1% suffered from epileptic seizures, mainly eyelid myoclonia with absences (55.3%). A total of 63 VEEGs were revised, observing a worsening of certain EEG findings with increasing age. A disorganized background was observed in all age ranges, yet this was more common among older cases. The main IEDs were bilateral synchronous and asynchronous posterior discharges, accounting for ≥50% in all age ranges. Generalized alterations with maximum amplitude in the anterior region showed as the second most frequent IED (≥15% in all age ranges) and were also more common with increasing age. Finally, diffuse fast activity was much more prevalent in cases with 6 years or older. To the best of our knowledge, this is the first study to analyze EEG features across different age groups, revealing an increase in interictal abnormalities over infancy and adolescence. Our findings suggest that SYNGAP1 haploinsufficiency has complex effects in human brain development, some of which might unravel at different developmental stages. Furthermore, they highlight the potential of baseline EEG to identify candidate biomarkers and the importance of natural history studies to develop specialized therapies and clinical trials.
Introduction
The SYNGAP1 gene, which is predominantly expressed in forebrain regions (Porter et al., 2005), encodes for a repressor of small GTPases, especially those from the Ras and Rap families (). In adult mammalian brains SynGAP is highly enriched at the postsynaptic density of excitatory synapses ( and ), where it is one of the most abundant proteins (). Because of this, the function of SynGAP is best understood in the context of synaptic biology, where it has a role in AMPA receptor (AMPAR) trafficking, synaptic plasticity and dendritic spine morphology (; ; Vazquez et al., 2004). Syngap1+/− mice consistently present increased levels of AMPARs at synapses, as well as hyperexcitability and a reduced seizures threshold (; ; ). In addition, more recent studies indicate that SynGAP would also have important roles during brain development, contributing to neuronal development (; ; ) or participating in the maturation of neuronal progenitors (). Thus, SynGAP is an important protein both for neuronal development and adult brain function.
De novo loss of function variants in the SYNGAP1 gene cause an autosomal dominant neurodevelopmental condition (), which is currently named SYNGAP1-related Developmental and Epileptic Encephalopathy (SYNGAP1-DEE, orphanet code: 544254). Variants in SYNGAP1 could represent one of the most prevalent monogenic forms of Intellectual Disability (ID) (1 case every 16.000 births, ), possibly explaining up to 1% of all ID cases (; ). Patients with pathogenic SYNGAP1 variants display multiple phenotypes with variable penetrance. Yet, developmental delay, moderate or severe ID and generalized epilepsies are present in the vast majority of cases (; ; Vlaskamp et al., 2019). Other common phenotypes include i) autism spectrum disorder (ASD)/autistic traits (signs or characteristics of autism without meeting all criteria for ASD), occurring in more than half of the affected individuals (; Vlaskamp et al., 2019), ii) severe sleep disturbances, identified in over 60% of cases (Smith-Hicks et al., 2021; ) or iii) behavioral problems, in more than 70% of cases (Vlaskamp et al., 2019). SYNGAP1-DEE appears to be equally prevalent in males and females and is found in all ethnic groups with similar prevalence.
Almost all subjects described in the literature with SYNGAP1-DEE present one or more forms of generalized seizures. Focal epilepsies are also reported but these are much less common. The age of seizure onset varies widely across the literature and, although it has been found as early as at 3 months of age, it is most commonly reported to start between the ages of 2 and 3 years (; ; Vlaskamp et al., 2019). Among the different forms of generalized seizures, SYNGAP1-DEE cases most frequently present eyelid myoclonia with absences, typical and atypical absences and myoclonic-atonic seizures (; ; Vlaskamp et al., 2019).
Some studies analyzing EEG recordings describe a certain predominance of IEDs in posterior regions of SYNGAP1-DEE cases, postulating that these might have potential value as biomarkers (; ; ; ). For instance, a slow or absent posterior dominant rhythm (PDR) has been proposed as a potential prognosis marker () and fixation-off sensitivity and eye closure sensitivity, which are posterior paroxysms appearing when eyes close, could be primary seizure triggers (). In this study, we have analyzed electroencephalographic findings in 36 individuals with pathogenic or likely pathogenic SYNGAP1 variants, focusing on the cortical distribution of IEDs and, specially, on the EEG changes observed along developmental time.
Materials and methods
Patient recruitment and clinical phenotyping
Individuals were referred through a Spanish network of collaborating child neurologists, geneticists, and psychiatrists, and through Asociación SYNGAP1 España. For one patient, the medical reference could not be reached, so an online interview was conducted with the caregiver. Inclusion criteria encompassed individuals with: i) a diagnosed developmental encephalopathy, either with or without epilepsy, ii) pathogenic or likely pathogenic SYNGAP1 variants, and iii) with at least one VEEG recording. A standardized phenotypic questionnaire was provided to referring physicians to assess clinical features, genetic pathogenic variants, developmental milestones, and epilepsy features (Supplementary Material).
The severity of intellectual disability (ID) was established with Intelligence Quotient (IQ) scores or information on the level of functioning in accordance with the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), . Behavioral abnormalities level was established based on the clinical evaluation of neuropediatricians or psychiatrists. Autism spectrum disorder (ASD) was assessed according to DSM-5 autism criteria. Global motor function was scored using the Gross Motor Function (GMF) scale (). Anthropometric data were converted to standard deviation scores (BMI Z-score and height Z-score) as recommended by the World Health Organization. The Sleep Disturbance Scale for Children (SDSC) () was used to identify sleep disorders. Seizure types were classified using the 2017 ILAE classification ().
Genetic studies
Genetics studies were performed following standard clinical protocols established in the hospitals participating in this study. Briefly, human SYNGAP1 variants were identified in DNA isolated from blood samples of affected individuals. In most cases SYNGAP1 variants were identified through exome sequencing using Illumina sequencing technology. In some instances, gene panels relevant to Neurodevelopmental Disorders (NDDs) were used. All variants identified were individually validated by standard Sanger sequencing with the same DNA samples.
SYNGAP1 gene variants were annotated and classified with Ensembl Variant Effect Predictor (), Annovar (Yang and Wang, 2015) and Varsome () using HG38 as the reference human genome. Of note, variants in this cohort that were classified as with unknown significance (VUS) by Varsome were further investigated. In these cases, we analyzed blood DNA samples from the parents using Sanger sequencing to confirm that the variation was de novo and reviewed if the variant had been described in the previous literature (; Vlaskamp et al., 2019). Final pathogenicity was stablished following the classification guidelines defined by the American College of Medical Genetics (ACMG) as we added and sum the additional criteria PS2 for de novo variants, thus shifting the classification of these variants from VUS to likely pathogenic.
VEEG collection and analysis
VEEG was performed at the reference medical centers of patients. When possible, VEEG recordings were sent to the Children’s Hospital Sant Joan de Déu (HSJD) for review. VEEGs were obtained with a minimum of 19 electrodes placed according to the 10/20 international system. The average recording time was 30 min, and sleep was observed in 38 of the 63 VEEGs. If the patient had more than one VEEG taken the same year, only the best quality one was included in the study. Thus, only one VEEG per year of life was taken into account for each individual. Initially, VEEGs were individually analyzed by the neurophysiologists or epileptologists of each center according to the standard clinical read (background activity, IEDs, ictal events and other alterations not associated to epileptogenesis). Later, these analyses were reviewed together in a retrospective study performed by the same neurophysiologist and neurologist at HSJD. Furthermore, two pediatric neurologists (HSJD) reviewed personal and family history (including antenatal/perinatal history) and seizures/epilepsy history, development and behavior, as well as physical and neurologic examination. The description of VEEG reports was made according to the glossary of terminology revised in 2017 () and the current classification of seizures according to the ILAE ().
Standard protocol approvals, registrations, and patient consents
All participants’ caregivers gave written informed consent. This study was approved by the local institutional Ethics Committee (Children’s Hospital Sant Joan de Déu ID number: PIC-232-20) and following the Declaration of Helsinki and relevant guidelines and regulations.
Statistical analysis of the frequency of VEGG abnormalities observed in SYNGAP1-DEE cases
For qualitative analysis of electroencephalographic abnormalities, patients were divided in four age groups, in which EEG findings do not experience large changes in the healthy population (): i) less than 3 years; ii) ≥ 3 and <6 years, iii) ≥ 6 and <10 years and iv) 10 or more years. The most common IEDs and their spatial maximum expression in the cortex were considered for statistical analyses. For the calculations of diffuse fast activity, patients with drugs that have a quantitative effect on EEG were excluded (). We applied binomial statistics to analyze if the frequency of VEEG abnormalities observed between age groups of SYNGAP1-DEE cases either increased or decreased. The null hypothesis tested was that no change in frequency would occur between age groups. This test was applied to the following VEEG parameters: i) background activity, ii) sleep architecture defined as the presence or absence of spindles, iii) bilateral synchronous and asynchronous occipital discharges, iv) generalized discharges with maximum in the anterior region, v) multifocal and focal IEDs and vi) fast activity.
Results
Genetic and clinical phenotyping of the cohort
We introduce a cohort of 36 individuals presenting clinical features compatible with the Developmental and Epileptic Encephalopathy caused by SYNGAP1. All cases present heterozygous genetic variants in the SYNGAP1 locus that are predicted to be pathogenic or likely pathogenic (Table 1 and Supplementary Table S1). The mean age of diagnosis was 8 years and 8 months (range: 2 years −17 years) and 55.9% of this cohort were males. To the best of our knowledge, of the 36 genetic variants present in this cohort, 18 had never been previously reported, nor in the published literature, neither in the curated database of clinical variants ClinVar (). Patient 29 presented an additional genomic modification compatible with Klinefelter Syndrome on a 60k array-CGH (arr(X)x2(Y)x1). Yet, this patient was included in the study because his clinical phenotype was consistent with SYNGAP1-DEE.
TABLE 1
| Patient ID | cDNA variant | Protein variant | Variant type | Exon | Protein domain# | Variant effect predictor | Varsome | De novo | Pathogenicity (ACMG)* | Previously reported ^ | Publication (Author, Year) | Existing variant (ClinVar) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | c.403C>T | p.Arg135* | Nonsense | 5/19 | PH | High | Pathogenic | Not available | Pathogenic | Yes | Mignot (2016) | rs1131692154 |
| 2 | c.2059C>T | p.Arg687* | Nonsense | 12/19 | GAP | High | Pathogenic | De novo | Pathogenic | Yes | Gao (2018) | rs1060503383 |
| 3 | c.3706 C>T | p.Gln1236* | Nonsense | 17/19 | DAB2P_C | High | Pathogenic | Not available | Pathogenic | Yes | rs1554122729 | |
| 4 | c.1393delC | p.Leu465Phefs*9 | Frameshift | 9/19 | GAP | High | Pathogenic | De novo | Pathogenic | Yes | Vlaskamp (2019) | rs1057518183 |
| 5 | c.3557C>A | p.Ser1186* | Nonsense | 16/19 | DAB2P_C | High | Pathogenic | De novo | Pathogenic | Yes | rs1554122485 | |
| 6 | c.2899C>T | p.Arg967* | Nonsense | 15/19 | DAB2P_C | High | Pathogenic | De novo | Pathogenic | Yes | Vlaskamp (2019) | rs749188610 |
| 7 | c.1726T>C | p.Cys576Arg | Missense | 11/19 | GAP | Moderate | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 8 | c.1783delC | p.Leu595Cysfs*55 | Frameshift | 11/19 | GAP | High | Pathogenic | De novo | Pathogenic | Yes | O'Roak (2014) | rs587780470 |
| 9 | c.3583-6G>A | p.Val1195Alafs*27 | Frameshift | Low | Likely pathogenic | Not available | Likely pathogenic | Yes | Lo Barco (2021) | rs869312674 | ||
| 10 | c.3524delG | p.Glu1176Lysfs*20 | Frameshift | 16/19 | DAB2P_C | High | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 11 | c.2270delG | p.Gly757Alafs*3 | Frameshift | 13/19 | DAB2P_C | High | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 12 | c.1722delG | p.Arg575Alafs*75 | Frameshift | 11/19 | GAP | High | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 13 | c.857T>C | p.Leu286Pro | Missense | 8/19 | C2 | Moderate | VUS | De novo | Likely pathogenic* | No | ||
| 14 | c.1167_1168delAG | p.Gly391Glnfs*27 | Frameshift | 8/19 | High | Pathogenic | De novo | Pathogenic | Yes | Michaelson (2018) | ||
| 15 | 6p21.32 | Not Applicable | Gene deletion | High | Not Applicable | De novo | Pathogenic | No | ||||
| 16 | c.2895delC | p.His966Thrfs*111 | Frameshift | 15/19 | DAB2P_C | High | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 17 | c.1163delG | p. Gly388Alafs*15 | Frameshift | 8/19 | High | Likely pathogenic | Not available | Likely pathogenic | No | |||
| 18 | c.793A>T | p.Lys265* | Nonsense | 8/19 | C2 | High | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 19 | c.1861C>T | p.Arg621* | Nonsense | 11/19 | GAP | High | Likely pathogenic | De novo | Likely pathogenic | Yes | Aguilera (2021) | rs1060503386 |
| 20 | c.844T>C | p.Cys282Arg | Missense | 8/19 | C2 | Moderate | VUS | De novo | Likely pathogenic* | Yes | Vlaskamp (2019) | rs1581987022 |
| 21 | c.797T>C | p.Leu266Pro | Missense | 8/19 | C2 | Moderate | VUS | De novo | Likely pathogenic* | No | ||
| 22 | 6p21.32-p21.31 | Not Applicable | Gene deletion | High | Not Applicable | De novo | Pathogenic | No | ||||
| 23 | c.3718C>T | p.Arg1240* | Nonsense | 17/19 | DAB2P_C | High | Pathogenic | Not available | Pathogenic | Yes | Vlaskamp (2019) | rs869312955 |
| 24 | c.1717C>T | p.Arg573Trp | Missense | 11/19 | GAP | Moderate | Pathogenic | De novo | Pathogenic | Yes | Pekeles (2019) | rs1064795331 |
| 25 | c.881C>A | p.Thr294Asn | Missense | 8/19 | C2 | Moderate | VUS | De novo | Likely pathogenic* | No | ||
| 26 | c.1167_1168delAG | p.Gly391Glnfs*27 | Frameshift | 8/19 | High | Pathogenic | Not available | Pathogenic | Yes | Michaelson (2018) | rs1060503378 | |
| 27 | c.1167_1168delAG | p.Gly391Glnfs*27 | Frameshift | 8/19 | High | Pathogenic | De novo | Pathogenic | Yes | Michaelson (2018) | rs1060503378 | |
| 28 | c.2091G>A | p.Trp697* | Nonsense | 12/19 | GAP | High | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 29 | c.2097_2098delGC | p.Leu700Alafs*39 | Frameshift | 12/19 | GAP | High | Likely pathogenic | Not available | Likely pathogenic | No | ||
| 30 | c.737T>C | p.Leu246Pro | Missense | 7/19 | PH | Moderate | Likely pathogenic | De novo | Likely pathogenic | No | ||
| 31 | c.509G>A | p.Arg170Gln | Missense | 5/19 | PH | Moderate | VUS | De novo | Likely pathogenic* | Yes | Parker (2015) | rs1057519546 |
| 32 | c.1735C>T | p.Arg579* | Nonsense | 10/19 | GAP | High | Likely pathogenic | Not available | Likely pathogenic | Yes | Hamdan (2009) | rs121918316 |
| 33 | c.2438delT | p.Leu813Argfs*23 | Frameshift | 15/19 | DAB2P_C | High | Pathogenic | Not available | Pathogenic | Yes | Hamdan (2009) | rs397515320 |
| 34 | c.1861C>T | p.Arg621* | Nonsense | 11/19 | GAP | High | Likely pathogenic | De novo | Likely pathogenic | Yes | Aguilera (2021) | rs1060503386 |
| 35 | c.2764C>T | p.Arg922* | Nonsense | 15/19 | DAB2P_C | High | Pathogenic | De novo | Pathogenic | Yes | Parker (2015) | rs1554122244 |
| 36 | c.1221_1224delGACA | p.Thr408* | Nonsense | 8/19 | GAP | High | Likely pathogenic | De novo | Likely pathogenic | No |
Genetic Variants Identified in our Cohort of SYNGAP1-DEE Cases and Prediction of Their Pathogenicity.
# Domains by InterPro. PH: Plekstrin Homology (IPR001849), C2 (IPR000008), GAP: GTPases activating protein (IPR001936), DAB2P_C: Disabled homolog 2-interacting protein, C-terminal domain (IPR021887).
* Pathogenicity stablished following American College of Medical genetics guidelines (ACMG); In patient 29 an arr(X)x2,(Y)x1 (Klinefelter Sd) was identified with a 60k array-CGH.
^ Present in ClinVar or published in previous literature.
Twenty-eight of these variants, representing over 75% of the total, are loss of function variants, that is they either: i) create a stop codon (Nonsense variants in Table 1, 13 cases), ii) delete of 1 or 2 nucleotides causing a frameshift that results in a downstream stop codon (Frameshift variants in Table 1, 13 cases) or iii) are big deletions encompassing the entire SYNGAP1 locus (Gene Deletion in Table 1, 2 cases). Of the two cases with large deletions, one affects 5 genes (KIFC1, PHF1, CUTA, SYNGAP1 and ZBTB9) and the other deletion affects 10 genes including SYNGAP1. The remaining 8 variants are missense, changing the aminoacidic sequence. Of note, we found two variants repeated in multiple independent cases. Cases 19 and 34 both had the nonsense variant c.1861C>T, and cases 14, 26 and 27 shared a deletion of two nucleotides (c.1167_ 1168delAG). We identified disease related variants in 11 of the 19 exons of the SYNGAP1 gene. Exons at 5′ and 3′ ends presented no pathogenic variants (Figure 1). We found 21 pathogenic variants in exons 8 to 12, which encode for the PH, C2 and GAP domains (Figure 1; Table 1). Exon 8 was specially populated with pathogenic variants, having 10. Thus, more than half of the variants identified concentrated in 5 of the 19 exons of the gene, which account for 1/3 of the base pairs of the canonical SYNGAP1 isoform (ENST00000455687.6).
FIGURE 1
Several in silico prediction tools were used to investigate the pathogenicity of these variants, including Ensembl Variant Effect Predictor (), Annovar (Yang and Wang, 2015) and Varsome (). Nevertheless, the final pathogenicity status was established following the guidelines of the ACMG (see Table 1). Based on these, we identified 16 Pathogenic and 21 Likely Pathogenic variants (Table 1). We established that all variants in this cohort classified as with unknown significance (VUS) by Varsome were de novo, because of this, and following ACMG guidelines we could finally classify these as Likely pathogenic (5 variants marked with* in Table 1).
Most members of this cohort were born at term (34 out of 36 patients) and all had normal birthweight for gestational age. All patients had global neurodevelopmental and language delays, as well as behavioral abnormalities. Intellectual disability (ID) was reported in all cases, albeit with different degrees: 11.7% had mild ID, 32.3% had moderate ID, 41.2% had severe ID and 14.7% had profound ID. Autistic traits were present in 91.7% of the cases in this cohort and 73% of the subjects experienced sleep disorders (Supplementary Table S1). Regarding behavioral abnormalities, aggression was observed in 72.7%, anxiety in 75.7%, flat affect in 37.5%, impulsiveness in 72.7% and inattentiveness in 87.9% of all cases.
Thirty-one patients had generalized seizures (96.9%), featuring eyelid myoclonia (55.3%), myoclonic-atonic seizures (35.3%), atonic seizures (44.1%) and atypical absences (25.5%) (Figure 2). In our cohort the proportion of subjects with pharmacoresistant epilepsy was found to be smaller when compared with previously published cohorts, as this was close to 40% (Supplementary Table S1), while previous reports indicate frequencies of up to 60% (; Vlaskamp et al., 2019).
FIGURE 2
VEEG findings observed along infancy, adolescence and young adulthood in SYNGAP1-DEE
Sixty-three VEEGs were analyzed, with 2 in the <3 years group, 20 in the 3 to less than 6 years group, 19 in the 6 to less than 10 years group, and 22 in the 10 or more years group. At least one scalp VEEG was performed in each case (range: 1 - 6 per case). The mean age of VEEG recordings was 8.2 years (range 2y-18y). Archived VEEG clips of seizures were available for 15 individuals and standardized epilepsy questionnaires, prepared according to the ILAE current classification of seizures, were performed in the remaining 21 cases. We collected multiple EEGs for each year of life between the ages of 2–16, while for ages 17, 18 and 20 we only had one recording. Seizures were registered in 12 VEEGs, all had generalized non-motor seizures, 9 had eyelid myoclonias with/without absence, 2 had absence seizures (typical or atypical) and 1 had both types of seizures. Fixation-off sensitivity (FOS) was observed in one patient, eye closure sensitivity (ECS) in 5 and photoparoxysmal response in 6. Two subjects had a combination of both, ECS with FOS or photoparoxysmal response (Supplementary Table S2).
Disorganized background activity (DBA), understood as a gross alteration in the frequency, shape, topography, and/or amount of physiological EEG rhythms compared to findings in normal subjects of similar age and state of alertness (), was observed in 51 out of 63 VEEG recordings, covering all age ranges. Nevertheless, DBA was more frequently observed in older age groups (Figures 3, 4). In the group of cases with 3 to less than 6 years of age DBA was observed in 75% of cases, while in the group with 6 to less than 10 years this increased to 95% and to 91% in the last age group (Figure 3A). Indeed, only 3 out of 41 EEGs recorded in children with 6 or more years, could be classified as having an organized background activity. Binomial statistics shows that the frequency of DBA is significantly higher in both older age groups as compared with cases between 3 and less than 6 years of age.
FIGURE 3
FIGURE 4
Sleep was recorded in 38 of 63 VEEGs (Supplementary Table S2), allowing us to assess the age-dependent organization of sleep architecture by analyzing the presence or absence of sleep spindles (; Schönauer and Pöhlchen, 2018; ). These graphoelements are the hallmark of the N2 stages of NREM sleep and evolve with a characteristic profile throughout life that parallels cortical maturation in early postnatal periods, throughout adolescence and aging (). We observed a very clear predominance of disorganized sleep architecture in all age groups (Figure 3B). Absence of sleep spindles was found in 89% of cases younger than 6 years, in 80% of patients between 6 and 10 years, and in 79% of cases in the 10 years and older group. No statistically significant differences were observed between the groups (binomial statistics).
Interictal epileptiform discharges (IEDs) were observed in 57 out of 62 VEEGS (information was not available in one EEG recording). Of the 5 VEEGs where IEDs were absent, 4 were in infants less than 6 years old (Supplementary Table S2). IEDs were classified into 4 types: i) “bilateral synchronous and asynchronous occipital discharges”, which was by far the most frequent IED (found in more than 50% of cases in all age ranges); ii) “generalized discharges with maximum amplitude in the anterior region”, the second interictal alteration in frequency, iii) multifocal and iv) focal IEDs (Figure 5A). When comparing the frequency of these IED types between age groups we observed that bilateral occipital discharges were less prevalent in cases 6 years or older. While discharges with a maximum in the anterior region had an opposed trend, appeared and worsened with age. Statistical analysis indicates that the reduction in bilateral posterior discharges between the group of 3 to ≤6 years and that of 6 to ≤10 is very close to significance (p = 0.051, binomial statistics) and the comparison between cases of 3 to ≤6 years and the group with the oldest cases is statistically significant (p = 0.028, binomial statistics). On the other hand, there is no difference in the frequency of these IEDs between the two groups of older cases. Indicating that the reduction in bilateral occipital discharges occurs between the ages of 6 and 9 and remains stable thereof. Concomitant to this reduction in occipital features, we observed an increase of generalized IEDs in anterior regions with age. Although this trend did not reach statistical significance.
FIGURE 5
To further investigate the changes in spatial distribution of IEDs with age we quantified their maximum expression, that is their maximum amplitude, in 5 cortical regions (Frontal, Temporal, Central, Parietal and Occipital). Overall, IEDs mostly appeared in frontal or occipital regions (Figure 5B), as only 1 EEG presented alterations in the parietal region, 2 in the central region and 3 in the temporal cortex (Figure 5C). In line with the analysis of IED types, we observed a clear reduction of aberrant activity in the occipital region along time (Figure 5B, dark green columns), although it did not completely disappear. In parallel, we observed the appearance and a clear increase in frontal discharges with age (Figure 5B, light green columns). These differences were more noticeable when comparing the group of 3 to ≤6 years with that of 10 years or older (p = 0.0015 for frontal cortex, p = 0.0029 for occipital cortex; binomial statistics). Indeed, there was no statistical difference when comparing cases in the second and third age groups for neither of the two cortical regions (Figure 5B). Instead, statistical significance was found when comparing the group of 6 to less than 10 years with the group of older cases (p = 0.015 in frontal cortex, p = 0.0029 in occipital cortex; binomial statistics). Finally, we also looked into diffuse fast activity, and we observed that this was much more frequent with increasing age. A clear increase in the frequency of EEGs presenting diffuse fast activity was detected when comparing the cases in the age group 3 to ≤6 years with those in the group of 6 to ≤10 years (p = 8,4e-07), or the group of 10 or older (p = 1,4e-10). The presence of this EEG feature was actually very rare in children younger than 6, as it was only identified in 2 out of 19 recordings. No statistical difference was observed between the two older age groups (Figure 5D).
We also investigated if there was a statistically significant correlation between the severity of clinical symptoms (including behavior abnormalities, ID, gross motor abilities and refractory epilepsy) and EEG findings (including background activity, maximum expression of IEDs or spatial distribution of the epileptiform discharges). No correlation could be detected for any of those comparisons between any of the age groups.
Discussion
In this study we introduce a new cohort of 36 SYNGAP1-DEE patients recruited through a network of Spanish neuropaediatricians. We have performed an extensive clinical phenotyping of this series, with especial emphasis on EEG features. We analyzed electroencephalographic characteristics across different age groups, ranging from 2 to 20 years, showing an increase in interictal abnormalities from infancy to young adulthood.
We used different bioinformatics methods to re-evaluate the pathogenicity of all SYNGAP1 variants in the cohort, which were initially characterized by more than 20 different Hospitals, confirming that all were pathogenic or likely pathogenic. Of note, 16 of these variants had, to the best of our knowledge, never been previously reported in the literature. We identified 28 loss of function genetic variants, two causing large deletions encompassing the entire SYNGAP1 locus or variants that result in premature stop codons, these represent over 75% of the total. On the other hand, missense variants account for the remaining 25% of the variants. Similar proportions of these variant types are reported in Varsome for a much larger number of variants. While the effect on protein function or stability of missense variants is difficult to predict, and these could result in a reduction of functional SynGAP protein, it is also plausible that SYNGAP1 alleles with missense variants will be expressed at normal levels. This would mean that other pathological mechanisms, beyond that of haploinsufficiency originally proposed (), might co-exist in SYNGAP1-DEE.
Overall, the main clinical phenotypes identified in this cohort, and their prevalence are well in line with previous reports (; ; ; Vlaskamp et al., 2019). All individuals displayed intellectual disability language delay and behavioral abnormalities. Additionally, sleep disorders, autism or autistic traits, and epilepsy were observed in most individuals. The main clinical difference between this cohort and previously reported ones would be the prevalence of cases diagnosed with autism spectrum disorders, which reached 73.5%, while the literature describes this to be observed in approximately half of the affected individuals. As a matter of fact, in total, 92% of our cohort was reported to present autistic traits. The relevance of this discrepancy would deserve further investigation, although it might be due to the extensive neuropsychological characterization of our series. If this is the case, the prevalence of autism among individuals with SYNGAP1-DEE might have been underestimated in previous studies.
Regarding epilepsy, 31 cases presented generalized seizures, featuring eyelid myoclonia, myoclonic-atonic seizures, atonic seizures and atypical absences. Furthermore, a number of cases presented with photosensitivity, FOS and ECS. All these findings are also in good agreement with the previous literature (; ; ; Vlaskamp et al., 2019) and indicate that the main symptoms of SYNGAP1-DEE are already well defined, as they are reproducible between cohorts from different countries and genetic ancestries. In our cohort the frequency of refractory epilepsies was found to be close to 40%, which is less than what has been reported in other studies (; Vlaskamp et al., 2019).
Having a cohort with an extended age range and having performed EEGs in all its members allowed us to investigate the temporal development of EEG features in SYNGAP1-DEE, with the goal to better understand the course of this condition. As EEG features change along normal development, we divided EEGs into age groups where these remain quite constant (). We defined 4 age groups of patients: i) those less than 3 years of age, ii) cases ≥3 and <6 years, iii cases) ≥ 6 and <10, and finally, iv) a group of cases with 10 or more years.
We first investigated the organization of EEG background activity. Developmental changes in background activity serve as a clear expression of functional brain maturation and connectivity (). Furthermore, background activity is an important parameter to evaluate brain dysfunction (Staba &Worrell, 2014), although its physiological mechanism is still poorly understood. During infancy, there is a progressive development of occipital alpha rhythms (8-12 Hz) while awakened and the appearance of vertex sharp transients and sleep spindles during sleep (). Conversely, poor sleep architecture has been observed in refractory epilepsy and epileptic encephalopathies (Proost et al., 2022), and there is a progressive increase in slow wave activities in encephalopathies, whether the cause is metabolic, septic, toxic or structural, the extent of which parallels the severity of the brain dysfunction (Smith, 2005).
Similar to what has been reported in the literature, in our cohort we observed that background activity, which could even be identified in cases of only 2 years of life, was disorganized in the majority of EEGs from SYNGAP1-DEE cases. Importantly, we observed that disorganized background activity (DBA) was more common in older age groups. This difference, which was statistically significant, was particularly remarkable if patients of 6 years or older were considered together, as only 3 out of 41 EEGs presented an organized background activity. This worsening of DBA with age might suggest that SynGAP protein function during nervous system development becomes increasingly complex or fundamental. Previous studies have shown a link between neurophysiological abnormalities and developmental outcomes. Among genetic neurodevelopmental encephalopathies, diffuse background slowing appears to increase with age in Dravet syndrome, an infantile-onset developmental and epileptic encephalopathy due to pathogenic variants in the SCN1A gene (). In Rett syndrome, a progressive neurological disorder due to pathogenic variants in the MECP2 gene, a progressive slowing of background activity is a hallmark of disease evolution (). Furthermore, DBA is observed in other encephalopathies, such as in inborn errors of metabolism, both in situations of acute encephalopathy and in neurodegenerative diseases (van Karnebeek et al., 2018). For instance, in an international study of argininosuccinate lyase deficiency, present with progressive intoxication due to accumulation of ammonia in the body, generalized background slowing was found in twelve out of nineteen patients (63%) (Elkhateeb et al., 2023). In turn, in neuronal ceroid lipofuscinoses (NCLs), a heterogeneous group of autosomal recessive neurodegenerative disorders, the EEG is marked by a progressive decline in cerebral activity, characterized by deceleration of background activity and the vanishing of spindles during sleep (Trivisano et al., 2022).
As sleep disorders are present in more than 60% of the SYNGAP1 population (Vlaskamp et al., 2019), we also examined sleep architecture by analyzing sleep spindles, an EEG signature that reflects the strength and malleability of thalamocortical circuits (Schönauer and Pöhlchen, 2018; ). As expected, most EEGs reflected a disorganized sleep architecture with reduced spindle activity in 82% of the VEEGs investigated. Reduced sleep spindles have been correlated with cognitive dysfunction and psychotic events (Schönauer and Pöhlchen, 2018; ). Their reduction may be of clinical relevance both for behavior and cognitive function in SYNGAP1-DEE.
We next investigated interictal epileptiform discharges (IED). The presence of epileptiform discharges with an occipital distribution is very common in infants and young children. They are found in 0.9% of normal preschool children and in 0.1% of typical older children (). These alterations occur in epilepsies of variable etiology and prognosis, ranging from structural, genetic, infectious, metabolic, autoimmune or even of unknown etiology. Less commonly, they occur in other forms of epilepsy, such as genetic generalized epilepsy (). The spatio-temporal expression of IED is consistent with brain maturation and tends to disappear or move to middle temporal regions in older children (). Studies analyzing EEG recordings on SYNGAP1-DEE cases describe a certain predominance of occipital epileptiform discharges (; ; ; ). The rationale for this phenomenon is not clear, since occipital epileptiform discharges in SYNGAP1 patients are mainly observed at 2-3 years, after the onset of epilepsy (; ; ), by which time the critical period of neuronal myelination has already ended (). A possible explanation for this phenomenon would be the hyperexcitability of the visual cortex observed in Syngap1+/− mice (; ). The fact that FOS, ECS and photosensibility are quite common in SYNGAP1-DEE strengthens this hypothesis, as these phenomena are an expression of occipital hyperexcitability (; Vaudano et al., 2017).
We also observed that the frequency of IEDs in anterior regions increase with age, especially in the frontal cortex. In our group of cases of 10 years or older the frequency of occipital and frontal epileptiform alterations as the main IED was 48% and 38% respectively, while in the age group of ≥3 and <6 years, occipital alterations accounted for 77%, while frontal only represented 18% of all IEDs. Furthermore, it is interesting to note that of the 62 VEEG recordings, 5 did not present any IEDs, of which 4 were recorded before the age of 6 years. These observations indicate that there is a deterioration in the electroencephalographic pattern of SYNGAP1-DEE cases.
To the best of our knowledge, this study is the first to show the presence of diffuse fast rhythms in SYNGAP1-DEE. We found that diffuse fast activity is almost completely absent before the age of 6, while afterwards it becomes highly predominant. The relationship between different forms of hyperexcitability and the development of abnormal neuronal rhythms is not yet fully understood, and the generation of excessive rhythmic activity in different frequency bands, with or without epileptic discharges, may support the diagnosis of genetic syndromes (). For example, high-amplitude rhythmic slow-wave activity has long been recognized as a feature of Angelman Syndrome; increased fast rhythms, beta and gamma waves, have been extensively reported in Fragile X Syndrome (), and high amplitude fast activity is often seen in patients with Beta-propeller Protein-Associated Neurodegeneration (BPAN), (), and Lissencephaly Syndrome (). These observations suggest that increased rhythmic alpha-beta activity may be an EEG pattern reflecting undetectable neuroradiological malformations or dysfunctional circuitry ().
This study has some limitations, mainly the relatively small number of cases in the cohort. A longitudinal study might have given more insight in the developmental progression of EEG findings in SYNGAP1-DEE. Furthermore, for several patients we only had access to VEEG reports, and a large part of neuropsychological assessments were based on the clinical impressions of referring physicians.
In conclusion, this study is the first to describe VEEGs changes occurring over the years in SYNGAP1-DEE. We observed a disorganized background activity that seems to worsen with age and a possible change in the pattern of IEDs, which shows an increasing involvement of anterior regions, especially the frontal cortex. Finally, we also observed that diffuse fast activity is much more frequent in older cases. These findings could suggest that SYNGAP1 haploinsufficiency has increasingly complex functions in human brain development that unfold along development. Or, alternatively, they could be the consequence of a highly disruptive distinctive event occurring early in neurodevelopment, that has a long-lasting negative impact on brain development. Clarifying which of these two hypotheses is correct is something that will require further investigation. Our findings support the potential of baseline EEG to identify candidate biomarkers and reinforces the importance of natural history studies to develop specialized therapies and clinical trials for SYNGAP1-DEE.
Statements
Data availability statement
The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
The study was approved by the local institutional Ethics Committee (Children’s Hospital Sant Joan de Déu ID number: PIC-232-20). The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.
Author contributions
JR-C: Conceptualization, Investigation, Validation, Writing–original draft. AT: Conceptualization, Investigation, Writing–review and editing. FM: Writing–review and editing. SI-M: Writing–review and editing. JP: Writing–review and editing. JR-F: Writing–review and editing. MM: Writing–review and editing. RC: Writing–review and editing. VS: Writing–review and editing. EG: Writing–review and editing. CV: Writing–review and editing. AF-J: Writing–review and editing. LP: Writing–review and editing. AC: Writing–review and editing. NV-R: Writing–review and editing. MM-T: Writing–review and editing. FP-C: Writing–review and editing. IM-C: Writing–review and editing. AH-F: Writing–review and editing. MT: Writing–review and editing. MSa: Writing–review and editing. LH: Writing–review and editing. PP: Writing–review and editing. TG: Writing–review and editing. MO': Writing–review and editing. FI: Writing–review and editing. MC: Writing–review and editing. MF: Writing–review and editing. AG-M: Investigation, Writing–review and editing. JS-C: Writing–review and editing. AM: Writing–review and editing. AL-A: Writing–review and editing. AC-G: Writing–review and editing. FV: Writing–review and editing. JC: Writing–review and editing. MSe: Investigation, Writing–review and editing. XA: Investigation, Writing–review and editing. DD-B: Investigation, Writing–review and editing. MS-P: Investigation, Writing–review and editing. SI: Investigation, Writing–review and editing. AR: Investigation, Writing–review and editing. OS: Investigation, Writing–review and editing. AG-C: Conceptualization, Investigation, Writing–original draft. AB: Conceptualization, Investigation, Writing–original draft. IA-C: Conceptualization, Investigation, Writing–original draft.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. AG-C is supported by FI21/0073 “Instituto de Salud Carlos III (ISCIII)” and “Fondo Europeo de desarrollo regional (FEDER)”. This work was supported by Asociación SYNGAP1 España. ATN was supported by a “Margarita Salas” contract from Next-Generation Europe and postdoc mobility grants “EMBO short exchange research” grant and “José Castillejo” grant. AB financial support was provided by: PID 2021-124411OB-I00 and RTI 2018-097037-B-I00 (MINECO/MCI/AEI/FEDER, EU), Award AC17/00005 by ISCIII through AES2017 and within the NEURON framework, Ramón y Cajal Fellowship (RYC-2011-08391p), IEDI-2017-00822 and AGAUR (2017 SGR 1776 and 2021 SGR 01005). The study was supported by the generous funding provided by the association of Spanish SYNGAP1-DEE families, SYNGAP1 España. AB and ATN thank the CERCA Programme/Generalitat de Catalunya for institutional support.
Acknowledgments
This work has been possible thanks to the collaboration of neurologists from all over the Spanish territory, and with the important contribution of the Asociación SYNGAP1 España, to which we would like to dedicate our deep gratitude for all the support. We also thank all the parents and caretakers on behalf of the patients, for participating in this study. We wish to thank Prof. Bru Cormand and Dr. Ferran Casas from the Universitat de Barcelona, for their advice on the bioinformatic analysis of genetic variants.
Conflict of interest
AG-C has received honoraria for research support and lectures from PTC Therapeutics, she has received honoraria for lectures from Biomarin, Immedica and Recordati Rare Diseases Foundation, and is a co-founder of the Hospital Sant Joan de Déu start-up “Neuroprotect Life Sciences”.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Correction note
A correction has been made to this article. Details can be found at: 10.3389/fcell.2026.1824815.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2024.1321282/full#supplementary-material
Abbreviations
ASD, Autism spectrum disorder; BW, Birthweight; ECS, Eye closure sensitivity; EEG, electroencephalogram; DBA, disorganized background activity; DEE, developmental and epileptic encephalopathy; FOS, Fixation-off sensitivity; GMF, Gross Motor Function; ID, Intellectual Disability; IEDs, Interictal Epileptiform Discharges; IQ, Intelligence Quotient; VEEG, Video electroencephalograms; PDR, Posterior dominant rhythm.
References
1
AdcockJ. E.PanayiotopoulosC. P. (2012). Occipital lobe seizures and epilepsies. J. Clin. neurophysiology official Publ. Am. Electroencephalogr. Soc.29 (5), 397–407. 10.1097/WNP.0b013e31826c98fe
2
AgarwalM.JohnstonM. V.StafstromC. E. (2019). SYNGAP1 mutations: clinical, genetic, and pathophysiological features. Int. J. Dev. Neurosci. official J. Int. Soc. Dev. Neurosci.78, 65–76. 10.1016/j.ijdevneu.2019.08.003
3
AguileraC.GabauE.Ramirez-MallafréA.Brun-GascaC.Dominguez-CarralJ.DelgadilloV.et al (2021). New genes involved in Angelman syndrome-like: expanding the genetic spectrum. PloS one16 (10), e0258766. 10.1371/journal.pone.0258766
4
AlfeiE.RaviglioneF.FranceschettiS.D'ArrigoS.MilaniD.SelicorniA.et al (2014). Seizures and EEG features in 74 patients with genetic-dysmorphic syndromes. Am. J. Med. Genet. Part A164A (12), 3154–3161. 10.1002/ajmg.a.36746
5
American Psychiatric Association (2013). Diagnostic and statistical manual of mental disorders. 5th ed. American: American Psychiatric Association. Available at: http://repository.poltekkes-kaltim.ac.id/657/1/Diagnostic%20and%20statistical%20manual%20of%20mental%20disorders%20_%20DSM-5%20%28%20PDFDrive.com%20%29.pdf.
6
BerryerM. H.HamdanF. F.KlittenL. L.MøllerR. S.CarmantL.SchwartzentruberJ.et al (2013). Mutations in SYNGAP1 cause intellectual disability, autism, and a specific form of epilepsy by inducing haploinsufficiency. Hum. Mutat.34 (2), 385–394. 10.1002/humu.22248
7
BirteleM.Del DossoA.XuT.NguyenT. H.WilkinsonB.HosseiniN.et al (2023). Non-synaptic function of the autism spectrum disorder-associated gene SYNGAP1 in cortical neurogenesis. Nat. Neurosci. Dec26 (12), 2090–2103. 10.1038/s41593-023-01477-3
8
BrittonJ. W.FreyL. C.HoppJ. L. al.LouisSt.E. K.FreyL. C. (2016). Electroencephalography (EEG): an introductory text and atlas of normal and abnormal findings in adults, children (Chicago: American Epilepsy Society). Available at: https://www.ncbi.nlm.nih.gov/books/NBK390343/.
9
BruniO.OttavianoS.GuidettiV.RomoliM.InnocenziM.CortesiF.et al (1996). The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J. sleep Res.5 (4), 251–261. 10.1111/j.1365-2869.1996.00251.x
10
ChenH. J.Rojas-SotoM.OguniA.KennedyM. B. (1998). A synaptic Ras-GTPase activating protein (p135 SynGAP) inhibited by CaM kinase II. Neuron20 (5), 895–904. 10.1016/s0896-6273(00)80471-7
11
ChengD.HoogenraadC. C.RushJ.RammE.SchlagerM. A.DuongD. M.et al (2006). Relative and absolute quantification of postsynaptic density proteome isolated from rat forebrain and cerebellum. Mol. Cell. proteomics MCP5 (6), 1158–1170. 10.1074/mcp.D500009-MCP200
12
ClementJ. P.AcetiM.CresonT. K.OzkanE. D.ShiY.ReishN. J.et al (2012). Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell.151 (4), 709–723. 10.1016/j.cell.2012.08.045
13
DattaA. N.WallbankL.MicallefJ.WongP. K. H. (2021). Pediatric occipital spikes at a single center over 26 Years and the significance of tangential dipole. J. child neurology36 (7), 530–536. 10.1177/0883073820984042
14
ElkhateebN.OlivieriG.SiriB.BoydS.StepienK. M.SharmaR.et al (2023). Natural history of epilepsy in argininosuccinic aciduria provides new insights into pathophysiology: a retrospective international study. Epilepsia64 (6), 1612–1626. 10.1111/epi.17596
15
FernandezL. M. J.LüthiA. (2020). Sleep spindles: mechanisms and functions. Physiol. Rev.100 (2), 805–868. 10.1152/physrev.00042.2018
16
FisherR. S.CrossJ. H.FrenchJ. A.HigurashiN.HirschE.JansenF. E.et al (2017). Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia58 (4), 522–530. 10.1111/epi.13670
17
GaoZ. J.JiangQ.ChenX. L.ChenQ.JiX. N.MaoY. Y.et al (2018). Study of de novo point mutations in known genes among patients with unexplained intellectual disability or developmental delay. Zhonghua yi xue za zhi98 (42), 3426–3432. 10.3760/cma.j.issn.0376-2491.2018.42.010
18
GilmoreJ. H.KnickmeyerR. C.GaoW. (2018). Imaging structural and functional brain development in early childhood. Nat. Rev. Neurosci.19 (3), 123–137. 10.1038/nrn.2018.1
19
GlazeD. G. (2005). Neurophysiology of rett syndrome. J. child neurology20 (9), 740–746. 10.1177/08830738050200090801
20
GmehlinD.ThomasC.WeisbrodM.WaltherS.PfüllerU.ReschF.et al (2011). Individual analysis of EEG background-activity within school age: impact of age and sex within a longitudinal data set. Int. J. Dev. Neurosci. official J. Int. Soc. Dev. Neurosci.29 (2), 163–170. 10.1016/j.ijdevneu.2010.11.005
21
GoodspeedK.ArmstrongD.DolceA.EvansP.SaidR.TsaiP.et al (2023). Electroencephalographic (EEG) biomarkers in genetic neurodevelopmental disorders. J. child neurology38 (6-7), 466–477. 10.1177/08830738231177386
22
GouG.Roca-FernandezA.KilincM.SerranoE.Reig-ViaderR.ArakiY.et al (2020). SynGAP splice variants display heterogeneous spatio-temporal expression and subcellular distribution in the developing mammalian brain. J. Neurochem.154 (6), 618–634. 10.1111/jnc.14988
23
HamdanF. F.GauthierJ.SpiegelmanD.NoreauA.YangY.PellerinS.et al (2009). Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation. N. Engl. J. Med.360 (6), 599–605. 10.1056/NEJMoa0805392
24
HyunJ.BaikM. J.KangU. G. (2011). Effects of psychotropic drugs on quantitative EEG among patients with schizophrenia-spectrum disorders. Clin. Psychopharmacol. Neurosci. official Sci. J. Korean Coll. Neuropsychopharmacol.9 (2), 78–85. 10.9758/cpn.2011.9.2.78
25
Jimenez-GomezA.NiuS.Andujar-PerezF.McQuadeE. A.BalasaA.HussD.et al (2019). Phenotypic characterization of individuals with SYNGAP1 pathogenic variants reveals a potential correlation between posterior dominant rhythm and developmental progression. J. Neurodev. Disord.11 (1), 18. 10.1186/s11689-019-9276-y
26
KahnA.DanB.GroswasserJ.FrancoP.SottiauxM. (1996). Normal sleep architecture in infants and children. J. Clin. neurophysiology13 (3), 184–197. 10.1097/00004691-199605000-00002
27
KaneN.AcharyaJ.BenickzyS.CabocloL.FinniganS.KaplanP. W.et al (2017). A revised glossary of terms most commonly used by clinical electroencephalographers and updated proposal for the report format of the EEG findings. Revision 2017. Revis. Clin. Neurophysiol. Pract.2, 170–185. 10.1016/j.cnp.2017.07.002
28
KatsanevakiD. (2018). Cortical circuit and behavioural pathophysiology in rodent models of SYNGAP1 haploinsufficiency. China: University of Edinburgh.
29
KidokoroH.YamamotoH.KubotaT.MotobayashiM.MiyamotoY.NakataT.et al (2020). High-amplitude fast activity in EEG: an early diagnostic marker in children with beta-propeller protein-associated neurodegeneration (BPAN). Clin. neurophysiology official J. Int. Fed. Clin. Neurophysiology131 (9), 2100–2104. 10.1016/j.clinph.2020.06.006
30
KilincM.CresonT.RojasC.AcetiM.EllegoodJ.VaissiereT.et al (2018). Species-conserved SYNGAP1 phenotypes associated with neurodevelopmental disorders. Mol. Cell. Neurosci.91, 140–150. 10.1016/j.mcn.2018.03.008
31
KimJ. H.LeeH. K.TakamiyaK.HuganirR. L. (2003). The role of synaptic GTPase-activating protein in neuronal development and synaptic plasticity. J. Neurosci. official J. Soc. Neurosci.23 (4), 1119–1124. 10.1523/JNEUROSCI.23-04-01119.2003
32
KomiyamaN. H.WatabeA. M.CarlisleH. J.PorterK.CharlesworthP.MontiJ.et al (2002). SynGAP regulates ERK/MAPK signaling, synaptic plasticity, and learning in the complex with postsynaptic density 95 and NMDA receptor. J. Neurosci. official J. Soc. Neurosci.22 (22), 9721–9732. 10.1523/JNEUROSCI.22-22-09721.2002
33
KopanitsaM. V.GouG.AfinowiN. O.BayésÀ.GrantS. G. N.KomiyamaN. H. (2018). Chronic treatment with a MEK inhibitor reverses enhanced excitatory field potentials in Syngap1+/- mice. Pharmacol. Rep. Aug70 (4), 777–783. 10.1016/j.pharep.2018.02.021
34
KopanosC.TsiolkasV.KourisA.ChappleC. E.Albarca AguileraM.MeyerR.et al (2019). VarSome: the human genomic variant search engine. Bioinforma. Oxf. Engl.35 (11), 1978–1980. 10.1093/bioinformatics/bty897
35
KoutroumanidisM.TsatsouK.SandersS.MichaelM.TanS. V.AgathonikouA.et al (2009). Fixation-off sensitivity in epilepsies other than the idiopathic epilepsies of childhood with occipital paroxysms: a 12-year clinical-video EEG study. Epileptic Disord. Int. epilepsy J. videotape11 (1), 20–36. 10.1684/epd.2009.0235
36
LandrumM. J.ChitipirallaS.BrownG. R.ChenC.GuB.HartJ.et al (2020). ClinVar: improvements to accessing data. Nucleic Acids Res.48 (D1), D835–D844. 10.1093/nar/gkz972
37
LlamosasN.AroraV.VijR.KilincM.BijochL.RojasC.et al (2020). SYNGAP1 controls the maturation of dendrites, synaptic function, and network activity in developing human neurons. J. Neurosci. official J. Soc. Neurosci.40 (41), 7980–7994. 10.1523/JNEUROSCI.1367-20.2020
38
Lo BarcoT.KaminskaA.SolazziR.CancésC.BarciaG.ChemalyN.et al (2021). SYNGAP1-DEE: a visual sensitive epilepsy. Clin. neurophysiology official J. Int. Fed. Clin. Neurophysiology132 (4), 841–850. 10.1016/j.clinph.2021.01.014
39
López-RiveraJ. A.Pérez-PalmaE.SymondsJ.LindyA. S.McKnightD. A.LeuC.et al (2020). A catalogue of new incidence estimates of monogenic neurodevelopmental disorders caused by de novo variants. Brain143 (4), 1099–1105. 10.1093/brain/awaa051
40
McLarenW.GilL.HuntS. E.RiatH. S.RitchieG. R.ThormannA.et al (2016). The Ensembl variant effect predictor. Genome Biol.17 (1), 122. 10.1186/s13059-016-0974-4
41
MichaelsonS. D.OzkanE. D.AcetiM.MaityS.LlamosasN.WeldonM.et al (2018). SYNGAP1 heterozygosity disrupts sensory processing by reducing touch-related activity within somatosensory cortex circuits. Nat. Neurosci.21 (12), 1–13. 10.1038/s41593-018-0268-0
42
MignotC.von StülpnagelC.NavaC.VilleD.SanlavilleD.LescaG.et al (2016). Genetic and neurodevelopmental spectrum of SYNGAP1-associated intellectual disability and epilepsy. J. Med. Genet.53 (8), 511–522. 10.1136/jmedgenet-2015-103451
43
MinatoE.MyersK. A. (2021). Age-related evolution of EEG in Dravet syndrome: meta-analysis of 155 patients. Seizure91, 108–111. 10.1016/j.seizure.2021.06.007
44
OkaM.KobayashiK.ShibataT.TsuchiyaH.HanaokaY.AkiyamaM.et al (2021). A study on the relationship between non-epileptic fast (40 - 200 Hz) oscillations in scalp EEG and development in children. Brain and Dev.43 (9), 904–911. 10.1016/j.braindev.2021.05.004
45
O'RoakB. J.StessmanH. A.BoyleE. A.WitherspoonK. T.MartinB.LeeC.et al (2014). Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nat. Commun.5, 5595. 10.1038/ncomms6595
46
PaaschV.DoucoureA.BifanoM.Smith-HicksC. L. (2023). An exploratory study of sleep quality and quantity in children with causal variants in SYNGAP1, an autism risk gene. Sleep. Med.107, 101–107. 10.1016/j.sleep.2023.04.008
47
PalisanoR.RosenbaumP.WalterS.RussellD.WoodE.GaluppiB. (1997). Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev. Med. child neurology39 (4), 214–223. 10.1111/j.1469-8749.1997.tb07414.x
48
ParkerM. J.FryerA. E.ShearsD. J.LachlanK. L.McKeeS. A.MageeA. C.et al (2015). De novo, heterozygous, loss-of-function mutations in SYNGAP1 cause a syndromic form of intellectual disability. Am. J. Med. Genet. Part A167A (10), 2231–2237. 10.1002/ajmg.a.37189
49
PekelesH.AccogliA.Boudrahem-AddourN.RussellL.ParenteF.SrourM. (2019). Diagnostic yield of intellectual disability gene panels. Pediatr. Neurol.92, 32–36. 10.1016/j.pediatrneurol.2018.11.005
50
PorterK.KomiyamaN. H.VitalisT.KindP. C.GrantS. G. (2005). Differential expression of two NMDA receptor interacting proteins, PSD-95 and SynGAP during mouse development. Eur. J. Neurosci.21 (2), 351–362. 10.1111/j.1460-9568.2005.03874.x
51
ProostR.LagaeL.Van PaesschenW.JansenK. (2022). Sleep in children with refractory epilepsy and epileptic encephalopathies: a systematic review of literature. Eur. J. Paediatr. neurology EJPN official J. Eur. Paediatr. Neurology Soc.38, 53–61. 10.1016/j.ejpn.2022.03.010
52
SchönauerM.PöhlchenD. (2018). Sleep spindles. Curr. Biol. CB28 (19), R1129–R1130. 10.1016/j.cub.2018.07.035
53
SmithS. J. (2005). EEG in neurological conditions other than epilepsy: when does it help, what does it add?J. neurology, Neurosurg. psychiatry76 (Suppl. 2), ii8–i12. ii8–ii12. 10.1136/jnnp.2005.068486
54
Smith-HicksC.WrightD.KennyA.StoweR. C.McCormackM.StanfieldA. C.et al (2021). Sleep abnormalities in the synaptopathies-SYNGAP1-related intellectual disability and phelan-McDermid syndrome. Brain Sci.11 (9), 1229. 10.3390/brainsci11091229
55
StabaR. J.WorrellG. A. (2014). What is the importance of abnormal “background” activity in seizure generation?Adv. Exp. Med. Biol.813, 43–54. 10.1007/978-94-017-8914-1_3
56
TrivisanoM.FerrettiA.CalabreseC.PietrafusaN.PiscitelloL.Carfi' PaviaG.et al (2022). Neurophysiological findings in neuronal ceroid lipofuscinoses. Front. neurology13, 845877. 10.3389/fneur.2022.845877
57
vtan KarnebeekC. D. M.SaysonB.LeeJ. J. Y.TsengL. A.BlauN.HorvathG. A.et al (2018). Metabolic evaluation of epilepsy: a diagnostic algorithm with focus on treatable conditions. Front. neurology9, 1016. 10.3389/fneur.2018.01016
58
VaudanoA. E.RuggieriA.AvanziniP.GessaroliG.CantalupoG.CoppolaA.et al (2017). Photosensitive epilepsy is associated with reduced inhibition of alpha rhythm generating networks. Brain a J. neurology140 (4), 981–997. 10.1093/brain/awx009
59
VazquezL. E.ChenH. J.SokolovaI.KnueselI.KennedyM. B. (2004). SynGAP regulates spine formation. J. Neurosci. official J. Soc. Neurosci.24 (40), 8862–8872. 10.1523/JNEUROSCI.3213-04.2004
60
VlaskampD. R. M.ShawB. J.BurgessR.MeiD.MontomoliM.XieH.et al (2019). SYNGAP1 encephalopathy: a distinctive generalized developmental and epileptic encephalopathy. Neurology92 (2), e96–e107. 10.1212/WNL.0000000000006729
61
WHO (2022). The WHO child growth standards. Available at: https://www.who.int/tools/child-growth-standards.
62
YangH.WangK. (2015). Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR. Nat. Protoc.10 (10), 1556–1566. 10.1038/nprot.2015.105
Summary
Keywords
SYNGAP1, rare disease, interictal epileptiform discharges, diffuse fast activity, autism spectrum disorder, EEG, disorganized background activity, developmental and epileptic encephalopathy
Citation
Ribeiro-Constante J, Tristán-Noguero A, Martínez Calvo FF, Ibañez-Mico S, Peña Segura JL, Ramos-Fernández JM, Moyano Chicano MC, Camino León R, Soto Insuga V, González Alguacil E, Valera Dávila C, Fernández-Jaén A, Plans L, Camacho A, Visa-Reñé N, Martin-Tamayo Blázquez MP, Paredes-Carmona F, Marti-Carrera I, Hernández-Fabián A, Tomas Davi M, Sanchez MC, Herraiz LC, Pita PF, Gonzalez TB, O'Callaghan M, Iglesias Santa Polonia FF, Cazorla MR, Ferrando Lucas MT, González-Meneses A, Sala-Coromina J, Macaya A, Lasa-Aranzasti A, Cueto-González AM, Valera Párraga F, Campistol Plana J, Serrano M, Alonso X, Del Castillo-Berges D, Schwartz-Palleja M, Illescas S, Ramírez Camacho A, Sans Capdevila O, García-Cazorla A, Bayés À and Alonso-Colmenero I (2024) Developmental outcome of electroencephalographic findings in SYNGAP1 encephalopathy. Front. Cell Dev. Biol. 12:1321282. doi: 10.3389/fcell.2024.1321282
Received
13 October 2023
Accepted
22 January 2024
Published
05 March 2024
Corrected
18 May 2024
Volume
12 - 2024
Edited by
Ana Cuenda, Spanish National Research Council (CSIC), Spain
Reviewed by
Andrea Lynne Gropman, Children’s National Hospital, United States
Michael Purcaro, Worcester Foundation for Biomedical Research, United States
Updates
Copyright
© 2024 Ribeiro-Constante, Tristán-Noguero, Martínez Calvo, Ibañez-Mico, Peña Segura, Ramos-Fernández, Moyano Chicano, Camino León, Soto Insuga, González Alguacil, Valera Dávila, Fernández-Jaén, Plans, Camacho, Visa-Reñé, Martin-Tamayo Blázquez, Paredes-Carmona, Marti-Carrera, Hernández-Fabián, Tomas Davi, Sanchez, Herraiz, Pita, Gonzalez, O'Callaghan, Iglesias Santa Polonia, Cazorla, Ferrando Lucas, González-Meneses, Sala-Coromina, Macaya, Lasa-Aranzasti, Cueto-González, Valera Párraga, Campistol Plana, Serrano, Alonso, Del Castillo-Berges, Schwartz-Palleja, Illescas, Ramírez Camacho, Sans Capdevila, García-Cazorla, Bayés and Alonso-Colmenero.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Itziar Alonso-Colmenero, itziar.alonso@sjd.es; Àlex Bayés, abayesp@santpau.cat
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.